Financial Data and Key Metrics Changes - Total clinic revenue for the full year reached $1,163 million, representing a 2% year-over-year growth [2] - Average revenue per customer rebounded significantly in Q4, reaching $316, an 11% increase year-over-year [3] - Net income attributable to shareholders grew 9% year-over-year to $51 million, and EPS increased 4% to $0.50 [5] - EBITDA was $70 million with an EBITDA margin of 40.4%, indicating strong profitability [5] Business Line Data and Key Metrics Changes - The company operated 283 locations and served 6.63 million customers over the trailing 12 months [2] - Aesthetic dermatology accounted for 70% of the company's performance, while aesthetic surgery made up 30% [21] - The AGA hair loss treatment network has become one of the largest in Japan, with ongoing expansions in orthopedics and fertility treatment [9] Market Data and Key Metrics Changes - The aesthetic dermatology market in Japan is growing at nearly 10% annually, while aesthetic surgery is growing at about 3% [21] - The domestic medical expenditure in Japan is approximately JPY 48 trillion annually, presenting a significant market opportunity [17] Company Strategy and Development Direction - The core strategic pillars include aesthetic dermatology, non-aesthetic healthcare, and global expansion, with a focus on longevity and AI-driven healthcare [6][7] - The company aims to launch SBC Wellness 2.0, integrating biomarker analysis and AI-powered diagnostics to create a new category of performance medicine [7][8] - Plans for international expansion include strategic investments in the U.S. and partnerships in Asia, focusing on building a strong operating platform [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovery in customer spending and growth in aesthetic medicine, with expectations of continued strong performance [15][16] - The company aims to achieve a number one position in various medical fields in Japan by 2035, leveraging its strengths in aesthetic medicine [18][19] - AI is seen as a foundational pillar for growth and efficiency, with plans to enhance operational capabilities through AI technologies [11][26] Other Important Information - The company has a robust capital allocation policy prioritizing growth investments while maximizing shareholder value [12] - A share buyback program was approved, allowing for flexible repurchase of shares if market conditions are favorable [41] Q&A Session Summary Question: Current status of the healthcare and aesthetic medicine market in Japan - Aesthetic dermatology is growing by 10% annually, while aesthetic surgery is growing at 3% [21] Question: Will SBC Wellness be a growth driver in FY 2026? - SBC Wellness is not expected to be a large revenue driver initially; the focus is on expanding the customer base [22][23] Question: What operational improvements are expected from AI? - AI will enhance efficiency in headquarters and clinics, with a focus on creating success cases for future external sales [26][27] Question: What is the future M&A strategy? - The company aims to engage in M&A to achieve a number one position in various medical fields by 2035 [28][29] Question: Next steps for OrangeTwist investment? - The company plans to leverage its expertise in aesthetic medicine and explore entry into the longevity market with OrangeTwist [31][32] Question: Any plans for medical tourism? - Currently, there are no plans for medical tourism related to fertility treatment in Mexico, but opportunities may exist in Asia [36] Question: Comments on the company's cash position? - The company has abundant cash for safe investments and M&A opportunities, allowing for flexible use of funds [37][38]

Financial Data and Key Metrics Changes - Total clinic revenue for the full year reached $1,163 million, representing a 2% year-over-year growth [2] - Average revenue per customer rebounded significantly in Q4, reaching $316, an 11% increase year-over-year [3] - Net income attributable to shareholders grew 9% year-over-year to $51 million, and EPS increased 4% to $0.50 [5] - EBITDA was $70 million with an EBITDA margin of 40.4% [5] Business Line Data and Key Metrics Changes - The company operated 283 locations and served 6.63 million customers over the trailing twelve months [2] - Aesthetic dermatology accounted for 70% of the company's performance, while aesthetic surgery accounted for 30% [21] - The AGA hair loss treatment network has grown to become one of the largest in Japan, with expansions in orthopedics and fertility treatment [9][10] Market Data and Key Metrics Changes - The aesthetic dermatology market in Japan is growing at approximately 10% annually, while aesthetic surgery is growing at about 3% [21] - The domestic Japanese market for medical expenditures is valued at JPY 48 trillion, with the company aiming to capture at least 10% of this market [17] Company Strategy and Development Direction - The core strategic pillars include aesthetic dermatology, non-aesthetic healthcare, and global expansion, with a focus on longevity and AI-driven healthcare [6] - The company is launching SBC Wellness 2.0, an upgraded corporate wellness platform integrating biomarker analysis and AI-powered diagnostics [6][7] - The multi-brand strategy aims to capture diverse customer needs and maximize lifetime value per customer [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovering customer spending and growth in aesthetic medicine, with expectations of continued strong performance [14][15] - The company aims to achieve a number one position in Japan's market for various medical fields by 2035 [19] - AI is seen as a foundational pillar for growth and efficiency, with plans to deploy AI across multiple operational areas [11] Other Important Information - The company is actively considering M&A opportunities to strengthen its market position in Japan and abroad [27][28] - A share buyback program was approved, allowing for flexible repurchases if market conditions are favorable [39] Q&A Session Summary Question: What is the current status of the healthcare and aesthetic medicine market in Japan? - The aesthetic dermatology market is growing by 10% annually, while aesthetic surgery is growing at 3% [21] Question: Will SBC Wellness be a growth driver in fiscal year 2026? - SBC Wellness is not expected to be a large revenue driver initially, but aims to expand the customer base [22] Question: What operational improvements are expected from AI? - AI will enhance efficiency in headquarters and clinics, with a focus on creating success cases this year [26] Question: What is the company's M&A strategy? - The company aims to achieve a number one position in various medical fields by 2035 and will engage in M&A if good opportunities arise [27][28] Question: What are the next steps for the investment in OrangeTwist? - The company plans to leverage its expertise in aesthetic medicine and explore opportunities in the longevity market with OrangeTwist [29][31] Question: How will the company utilize its cash reserves? - The company has abundant cash for safe investments and plans to use it flexibly for M&A opportunities [35]

Investor Presentation 4Q and Full Year 2025 March 2026 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company' ...

Core Viewpoint - Jack Nathan Medical Corp. is undergoing a leadership transition and strategic alignment to support its growth, optimize its balance sheet, and evaluate potential value-enhancing transactions [1][2]. Leadership Transition - Mike Marchelletta has stepped down as CEO and Vice-Chairman to lead a prospective investor syndicate for a potential strategic transaction [2]. - Michael Di Cesare, former co-founder and COO, has been appointed as Interim CEO and Vice-Chairman, bringing operational continuity and strategic insight [3]. Financial Restructuring - The company has eliminated approximately $15 million in debt and canceled about 140 million common shares previously issuable under legacy debenture financing, enhancing its capital structure and strategic flexibility [4]. - Governance measures have been implemented to strengthen shareholder confidence and long-term value creation [4][9]. Strategic Focus - The leadership transition aims to unlock new pathways for capital, partnerships, and growth, maximizing value for shareholders [5]. - The company is focused on advancing its restructuring initiatives and evaluating new growth opportunities [3][5]. Company Background - Jack Nathan Medical Corp. previously operated one of the largest retail medical clinic networks in North America, with 253 locations globally, including 82 in Canada and 171 in Mexico [10]. - The company has restructured its Canadian operations and is exploring new reverse takeover and business opportunities following its exit from Walmart Mexico operations [10].

Core Points - Datametrex AI Limited has announced the expansion of same-day medical care through walk-in services at its Calgary and Edmonton clinics [1] Group 1 - The expansion is executed by Imagine Health Medical Clinics Ltd., a wholly owned subsidiary of Datametrex [1]

Core Viewpoint - Datametrex AI Limited's subsidiary, Imagine Health Medical Clinics Ltd., has successfully relocated its Edmonton South clinic, indicating growth and operational expansion for the company [1]. Company Summary - Datametrex AI Limited operates in the healthcare sector through its subsidiary, Imagine Health Medical Clinics Ltd. [1]. - The relocation of the Edmonton South clinic suggests a strategic move to enhance service delivery and accessibility for patients [1].

Core Points - Datametrex AI Limited's subsidiary, Imagine Health Medical Clinics Ltd., has relocated its Calgary clinic to a more convenient residential area in Capitol Hill [1] Company Summary - The relocation of the Calgary clinic aims to enhance accessibility for patients [1] - Imagine Health continues to expand its presence in the healthcare sector through strategic location choices [1] Industry Summary - The move reflects a trend in the healthcare industry towards improving patient access and convenience [1] - Relocations to residential areas may indicate a growing focus on community-based healthcare services [1]

Investor Presentation August 2025 2Q2025 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's financial pe ...